AU2010305825A1 - Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor - Google Patents

Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor Download PDF

Info

Publication number
AU2010305825A1
AU2010305825A1 AU2010305825A AU2010305825A AU2010305825A1 AU 2010305825 A1 AU2010305825 A1 AU 2010305825A1 AU 2010305825 A AU2010305825 A AU 2010305825A AU 2010305825 A AU2010305825 A AU 2010305825A AU 2010305825 A1 AU2010305825 A1 AU 2010305825A1
Authority
AU
Australia
Prior art keywords
esi
methyl
pct
alkyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010305825A
Other languages
English (en)
Inventor
Thomas Russell Clarkson
Fiona Jeremiah
John Kinnaird Ferguson Maclean
Paul David Ratcliffe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme BV filed Critical Merck Sharp and Dohme Ltd
Publication of AU2010305825A1 publication Critical patent/AU2010305825A1/en
Assigned to MERCK SHARP & DOHME B.V. reassignment MERCK SHARP & DOHME B.V. Alteration of Name(s) of Applicant(s) under S113 Assignors: MSD OSS B.V.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2010305825A 2009-10-13 2010-10-11 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor Abandoned AU2010305825A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25110109P 2009-10-13 2009-10-13
EP09172872 2009-10-13
EP09172872.5 2009-10-13
US61/251,101 2009-10-13
PCT/EP2010/065160 WO2011045258A1 (en) 2009-10-13 2010-10-11 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor

Publications (1)

Publication Number Publication Date
AU2010305825A1 true AU2010305825A1 (en) 2012-04-19

Family

ID=42040651

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010305825A Abandoned AU2010305825A1 (en) 2009-10-13 2010-10-11 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor

Country Status (12)

Country Link
US (1) US8841289B2 (enExample)
EP (1) EP2488520B1 (enExample)
JP (1) JP2013507417A (enExample)
KR (1) KR20120100913A (enExample)
CN (1) CN102666540A (enExample)
AU (1) AU2010305825A1 (enExample)
BR (1) BR112012008518A2 (enExample)
CA (1) CA2776835A1 (enExample)
IN (1) IN2012DN02968A (enExample)
MX (1) MX2012004289A (enExample)
RU (1) RU2012119488A (enExample)
WO (1) WO2011045258A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2843383A1 (en) 2011-07-29 2013-02-07 Taisho Pharmaceutical Co., Ltd. Amidine compound or salt thereof
EP2822656B1 (en) 2012-03-07 2016-10-19 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
CA2874193A1 (en) * 2012-05-22 2013-11-28 Vladimir BAJIC Combination comprising parthenolide for use in the treatment of alzheimer's disease and other neurodegenerative disorders
US9611223B2 (en) 2013-09-11 2017-04-04 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
EP3191459A1 (en) 2014-09-05 2017-07-19 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
EP3233087B1 (en) 2014-12-16 2019-10-02 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
JP2018504430A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのキナゾリノン及びアザキナゾリノン
JP2018504431A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのチエノピリミジノン
EP3253759A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
CN106146410B (zh) * 2015-04-03 2018-10-12 中南大学 6-氨基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
CN106279211B (zh) * 2015-06-03 2020-09-15 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
JP2018516973A (ja) 2015-06-10 2018-06-28 フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． α７−ニコチン性アセチルコリン受容体のアゴニストとしてのアミノベンゾイソオキサゾール化合物
WO2017027600A1 (en) 2015-08-12 2017-02-16 Forum Pharmaceuticals, Inc. GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS
PL3386591T3 (pl) 2015-12-09 2021-02-22 Novartis Ag Heteroaromatyczne modulatory receptorów nmda i ich zastosowania
ES2950348T3 (es) 2015-12-09 2023-10-09 Novartis Ag Moduladores de receptores NMDA de tienopirimidinona y usos de los mismos
EP3558318B1 (en) 2016-12-22 2023-12-20 Novartis AG Nmda receptor modulators and uses thereof
CA3105174A1 (en) * 2018-06-27 2020-01-02 Reborna Biosciences, Inc. Prophylactic or therapeutic agent for spinal muscular atrophy
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
US20220089609A1 (en) 2018-07-26 2022-03-24 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
RS64359B1 (sr) 2018-08-03 2023-08-31 Novartis Ag Heteroaromatični modulatori nmda receptora i njihove upotrebe
WO2021198188A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
WO2021198191A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
US12180193B2 (en) 2020-08-28 2024-12-31 Arvinas Operations, Inc. Accelerating fibrosarcoma protein degrading compounds and associated methods of use
CN112898290B (zh) * 2021-01-29 2022-08-05 中南大学 异噁唑甲酰胺基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
TW202539670A (zh) * 2024-02-23 2025-10-16 大陸商海思科醫藥集團股份有限公司 Braf抑制劑的製備方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
JP2005504730A (ja) * 2001-04-20 2005-02-17 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｇｓｋ−３インヒビターとして有用な組成物
WO2003062235A1 (en) * 2002-01-17 2003-07-31 Eli Lilly And Company Modulators of acetylcholine receptors
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
TW200536830A (en) * 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
PT1910333E (pt) * 2005-07-26 2013-08-01 Sanofi Sa Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase
JP5256202B2 (ja) 2006-09-11 2013-08-07 エム・エス・ディー・オス・ベー・フェー キナゾリノンおよびイソキノリノンアセトアミド誘導体
KR101545533B1 (ko) * 2006-12-27 2015-08-19 사노피 치환된 이소퀴놀린 및 Ｒｈｏ-키나아제 억제제로서의 이의 용도
JP2010229035A (ja) 2007-08-01 2010-10-14 Taisho Pharmaceutical Co Ltd ピリドピリミジン−４−オン誘導体
RU2010114662A (ru) * 2007-11-14 2011-12-20 Ньюросёрч А/С (Dk) Новые производные 1,4-диазабицикло(3.2.2)нонилпиримидина и их медицинское применение
US20100327809A1 (en) 2008-02-29 2010-12-30 Techno Core International Co., Ltd. Charging apparatus and quality judging apparatus for packed battery

Also Published As

Publication number Publication date
EP2488520B1 (en) 2015-09-02
RU2012119488A (ru) 2013-11-20
BR112012008518A2 (pt) 2016-04-05
US8841289B2 (en) 2014-09-23
IN2012DN02968A (enExample) 2015-07-31
MX2012004289A (es) 2012-06-12
KR20120100913A (ko) 2012-09-12
CN102666540A (zh) 2012-09-12
US20120208796A1 (en) 2012-08-16
JP2013507417A (ja) 2013-03-04
WO2011045258A1 (en) 2011-04-21
EP2488520A1 (en) 2012-08-22
CA2776835A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
AU2010305825A1 (en) Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor
CN116194456B (zh) 作为kras抑制剂的杂环化合物的制备及其应用方法
AU2019309987B2 (en) Heterobicyclic compounds for inhibiting the activity of shp2
JP6128133B2 (ja) Ｉｇｆ−１ｒ／ｉｒ阻害剤としての５，８−ジヒドロ−６ｈ−ピラゾロ［３，４−ｈ］キナゾリン
JP2022510980A (ja) ヘテロ芳香族誘導体調節因子、その製造方法及び使用
CN113061132B (zh) 一类稠环内酰胺类化合物、制备方法和用途
JP2021518395A (ja) Ｓｈｐ２阻害剤およびその使用
CA2825279A1 (en) New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
JP2019537610A (ja) Ｆｇｆｒ４阻害剤、その製造方法と薬学的な応用
CN112778311B (zh) 含氮并环类衍生物抑制剂、其制备方法和应用
WO2014060112A1 (en) Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
UA101676C2 (uk) Піримідинові сполуки, композиції і способи застосування
CA2767648A1 (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
KR20090038895A (ko) 융합된 피리미도 화합물
CA2803467A1 (en) New aminopyrazoloquinazolines
AU2021373162B2 (en) Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof
JP7801084B2 (ja) Ｅｇｆｒ阻害剤としてのインドリン化合物及び誘導体
EP4008719A2 (en) Pyrazolone and pyrimidine compound, and preparation method and use therefor
AU2022371404A1 (en) Covalent egfr inhibitors and methods of use thereof
WO2009043884A1 (en) Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine d3 receptors
AU2022378269A1 (en) Quinazoline derivative compound and use thereof
CA2716202A1 (en) Pyrrolo[2,3-d]pyrimidin-2-yl-amine derivatives as pkc-theta inhibitors
CA3255932A1 (en) ACTIVE COMPOUNDS AGAINST BROMODOMAINS
TW202246261A (zh) 作為抗癌劑的化合物

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application